SCHEMBL23948426

SCHEMBL23948426

O=c1ccn2ncc(-n3cccn3)c2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.40
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
G6PD P11413 1/20 0.38
KMT2A Q03164 1/20 0.38
MAPK1 P28482 2/20 0.37
NPC1 O15118 1/20 0.37
ADRA2A P08913 1/20 0.35
ADRA1A P35348 1/20 0.35
KDM5B Q9UGL1 2/20 0.33
NOTUM Q6P988 1/20 0.33
KDM4A O75164 1/20 0.33
KDM4B O94953 1/20 0.33
KDM5C P41229 1/20 0.33
JAK2 O60674 1/20 0.33
TYK2 P29597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23948296 0.77 TDO2 (0.41) TDO2KDM4EALDH1A1MAPTMAPK1
SCHEMBL23947980 0.76 HCAR1 (0.35) KDM5BNOTUMHCAR1EGLN1
SCHEMBL23948322 0.75 MELK (0.40) CYP2C9HCAR1
SCHEMBL23948328 0.75 ABL1 (0.38) ALDH1A1KMT2ACYP1A2
SCHEMBL23947915 0.74 HCAR1 (0.36) PDE9ACYP46A1HCAR1EGLN1
SCHEMBL23948427 0.73 PLAT (0.33) EGLN1
SCHEMBL23947948 0.73 KDM4A (0.33) KDM5BKDM4AKDM4BKDM5C
SCHEMBL26306183 0.73 HCAR1 (0.34) HCAR1
SCHEMBL23948432 0.73 IRAK4 (0.30)
SCHEMBL26306212 0.73 IRAK4 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. 2023-08-03 US disclosed
WO-2021211882-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS PYRAMID BIOSCIENCES, INC. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242536-A1 METHODS FOR PREPARING TYROSINE RECEPTOR KINASE INHIBITORS LTK, FRK, LCK TDO2 1375/4885KDM4E 1646/4885ALDH1A1 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.